Multicell Technologies Inc. (MCET)

Overview

MultiCell Technologies, Inc. is a pioneering biopharmaceutical company focused on the discovery and development of novel therapeutics and tools for a variety of significant medical needs. Specifically, their endeavors are aimed at addressing neurological disorders, hepatic diseases, cancer, and applications in interventional cardiology and peripheral vessels. Founded in 1962 and based in Woonsocket, Rhode Island, the company has evolved through various phases, notably changing its name from Exten Industries, Inc. to MultiCell Technologies, Inc. in April 2004. Through strategic partnerships, including license agreements with Corning Incorporated and Pfizer Inc., MultiCell Technologies is positioned at the forefront of medical research and development in its target areas.

Products and Services

• MCT-125

  A Phase II therapeutic candidate tailored for the treatment of primary multiple sclerosis-related fatigue. MCT-125 represents a significant step forward in addressing an often debilitating symptom of multiple sclerosis, providing hope for improved quality of life for patients.

• MCT-465

  A preclinical, synthetic double-stranded RNA (dsRNA) therapeutic candidate recognized for its potent immune enhancing properties. This product is designed to target solid tumor cancers, presenting a new avenue for cancer treatment that leverages the body's own immune system to combat the disease.

• MCT-485

  At the discovery stage, MCT-485 is another dsRNA therapeutic candidate, but with unique tumor cytolytic properties. It stands out for its potential to directly kill various cancer cells, reflecting MultiCell Technologies' diverse approach to tackling cancer through innovative mechanisms.

• Ideal BioStent

  This bioabsorbable stent is being developed for use in interventional cardiology and peripheral vessel applications. The Ideal BioStent represents a major innovation in the field, aiming to improve patient outcomes by providing a temporary scaffolding that naturally dissolves over time, reducing the need for additional interventions.